Generic competition forces J&J's Q3 pharma sales down by 14%
This article was originally published in Scrip
Johnson & Johnson has reported a 14% drop in pharmaceutical sales in the third quarter, to $5.3 billion. The company as a whole saw revenues decline by 5% to $15.1 billion, partly because of negative currency effects (which dragged down the result by 2.5%) but to a greater extent because of generic competition for its pharmaceutical products, particularly in the US.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.